Contemporary Endovascular 30-Day Outcomes for Critical Limb Threatening Ischemia Relative to Surgical Bypass Grafting.


Journal

Vascular and endovascular surgery
ISSN: 1938-9116
Titre abrégé: Vasc Endovascular Surg
Pays: United States
ID NLM: 101136421

Informations de publication

Date de publication:
Jul 2021
Historique:
pubmed: 20 2 2021
medline: 9 7 2021
entrez: 19 2 2021
Statut: ppublish

Résumé

Data from 2011-2014 showed lower extremity bypass(LEB) outperforming infrainguinal endovascular intervention(IEI) regarding major adverse limb events(MALE) but noted no significant difference in major adverse cardiac events(MACE) in propensity matched cohorts. This study aimed to determine if more recent(2015-2018) endovascular outcomes data have improved relative to surgical bypass. Patients who underwent intervention for chronic limb threatening ischemia (CLTI) from 2015-2018 were identified using the American College of Surgeons National Quality Improvement Program(NSQIP) Vascular Surgery module. The cohort was categorized as undergoing lower extremity bypass(LEB) or infrainguinal endovascular intervention(IEI). Primary 30-day outcomes included major adverse cardiac events(MACE), major adverse limb events(MALE), and major amputation. Inverse probability weighting was used for multivariable analysis. A total of 10,783 patients underwent an infrainguinal intervention for CLTI from 2015-2018. Of these, 6,003(55.7%) underwent LEB and 4,780(44.3%) underwent IEI. Forty percent of the cohort was considered "high anatomic risk" by Objective Performance Goals(OPG) standards, and 13.6% were considered "high clinical risk." The IEI cohort vs. the LEB cohort experienced a Myocardial infarction(MI)/Stroke rate of 1.8% vs. 3.6%(p < .001), and had a mortality rate of 2.0% vs. 1.7%(p = .22), which yielded a composite MACE of 3.4% vs. 4.8%(p = .001). The rate of reintervention for IEI vs LEB was 4.4% vs. 5.3%(p = .04), the loss of patency (without re-intervention) rate was 1.8% vs. 1.8%(p = 1.0), and the major amputation rate was 4.1% vs. 3.5%(p = .15), which resulted in a MALE rate of 9.1% vs. 8.8%(p = .50). Following inverse probability weighting, comparing the IEI to the referent LEB, MALE AOR = 1.17, 95% CI[1.01 -1.36], p = .036, MACE AOR = 0.61, 95% CI[0.49-0.74], p < .001, and major amputation AOR = 1.31, 95% CI[1.05 -1.62], p = .016. Endovascular outcomes continue to demonstrate inferiority in major amputation and overall MALE. However, endovascular intervention has a significantly reduced incidence of MACE. Overall, these results demonstrate an improvement in endovascular MACE rates in recent years relative to surgical bypass.

Identifiants

pubmed: 33602047
doi: 10.1177/1538574421989516
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

441-447

Auteurs

Christopher Alan Latz (CA)

Division of Vascular and Endovascular Surgery, 2348Massachusetts General Hospital, Boston, MA, USA.

Laura Boitano (L)

Division of Vascular and Endovascular Surgery, 2348Massachusetts General Hospital, Boston, MA, USA.

Linda J Wang (LJ)

Division of Vascular and Endovascular Surgery, 2348Massachusetts General Hospital, Boston, MA, USA.

Anna A Pendleton (AA)

Division of Vascular and Endovascular Surgery, 2348Massachusetts General Hospital, Boston, MA, USA.

Charles DeCarlo (C)

Division of Vascular and Endovascular Surgery, 2348Massachusetts General Hospital, Boston, MA, USA.

Brandon Sumpio (B)

Division of Vascular and Endovascular Surgery, 2348Massachusetts General Hospital, Boston, MA, USA.

Samuel Schwartz (S)

Division of Vascular and Endovascular Surgery, 2348Massachusetts General Hospital, Boston, MA, USA.

Sunita Srivastava (S)

Division of Vascular and Endovascular Surgery, 2348Massachusetts General Hospital, Boston, MA, USA.

Anahita Dua (A)

Division of Vascular and Endovascular Surgery, 2348Massachusetts General Hospital, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH